Actively Recruiting
Assessing Antiviral Treatments in Early Symptomatic RSV
Led by University of Oxford · Updated on 2025-07-02
1000
Participants Needed
2
Research Sites
127 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory Syncytial Virus (RSV), to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential adaptive platform trial, we will assess and compare the performance of currently licensed interventions (including repurposed drugs) with activity against RSV, and those with potential activity demonstrated in pre-clinical and early clinical studies relative to each-other, and the control (no antiviral treatment). ARSYNAL-FC study is funded by Wellcome Trust Grant ref: 226933/Z/23/Z through the COVID-19 Therapeutics Accelerator
CONDITIONS
Official Title
Assessing Antiviral Treatments in Early Symptomatic RSV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient understands the study and can give informed consent
- Adults aged 18 to under 65 years at consent
- Early symptomatic RSV with at least one symptom within 4 days
- RSV positive by rapid antigen or PCR test within last 24 hours with Ct <30
- Able to walk unaided and perform daily activities
- Willing and able to follow all study procedures and attend follow-up visits
You will not qualify if you...
- Taking medications that could interact with study drugs or have antiviral activity
- Chronic illness or significant comorbidity requiring long-term treatment
- Body mass index 35 kg/m2 or higher
- Significant lab abnormalities at screening including low hemoglobin, low platelets, elevated liver enzymes, or reduced kidney function
- Pregnant, breastfeeding, or trying to become pregnant (except women on oral contraceptives)
- Allergy or contraindication to study drugs
- Participating in another interventional RSV, influenza, or COVID-19 trial
- Signs of pneumonia such as shortness of breath or hypoxemia
- Currently co-infected with influenza or SARS-CoV-2
- Received RSV vaccine within the past year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Laos-Oxford-Mahosot Hospital-Wellcome Trust Research Unit
Vientiane, Laos, 01000
Actively Recruiting
2
Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand, 10400
Actively Recruiting
Research Team
W
William Schilling, MD
CONTACT
N
Nicholas J White, Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here